[go: up one dir, main page]

WO1999036087A1 - Nouvelles compositions de vaccin contre le virus de l'herpes simplex - Google Patents

Nouvelles compositions de vaccin contre le virus de l'herpes simplex Download PDF

Info

Publication number
WO1999036087A1
WO1999036087A1 PCT/US1999/000922 US9900922W WO9936087A1 WO 1999036087 A1 WO1999036087 A1 WO 1999036087A1 US 9900922 W US9900922 W US 9900922W WO 9936087 A1 WO9936087 A1 WO 9936087A1
Authority
WO
WIPO (PCT)
Prior art keywords
hsv
virus
vaccine composition
subject
simplex virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000922
Other languages
English (en)
Inventor
Laure Aurelian
Michael Kulka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AuRx Inc
Original Assignee
AuRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AuRx Inc filed Critical AuRx Inc
Priority to AU22314/99A priority Critical patent/AU2231499A/en
Publication of WO1999036087A1 publication Critical patent/WO1999036087A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention discloses new vaccine compositions for He ⁇ es Simplex comp ⁇ sing a whole live HSV-2 virus having vanous ammo acids deleted. Methods of using the vaccine compositions are also included.
  • HSV- 1 and HSV-2 Both distinguishable serotypes of He ⁇ es Simplex V irus (HSV- 1 and HSV-2) cause infection and disease ranging from relatively minor fever blisters on lips to severe genital infections, and generalized infections of newborns HSV- 1 and HSV-2 are 50% homologous at the DNA level, and polyclonal antibodies and MAbs to shared epitopes are cross-reactive.
  • HSV-1 and HSV-2 have ⁇ bonucleotide reductase 1 (RR1 ) proteins (an alloste ⁇ c subunit of the ⁇ bonucleotide reductase (RR) enzyme) (respectively designated ICP6 and ICP10) that contain a unique ammo terminal domain
  • RR1 ⁇ bonucleotide reductase 1
  • ICP6 and ICP10 ⁇ bonucleotide reductase 1
  • ICP6 and ICP10 ⁇ bonucleotide reductase 1
  • the HSV-2 unique domain codes for a se ⁇ ne/threonine-specific protein kinase (PK) which has auto- and transphosphorylating activity and has a transmembrane (TM) domain Sequences which code for the PK domain cause neoplastic transformation and are associated with cervical cancer ( HSV-2 oncogene)
  • PK se ⁇ ne/threonine-specific protein kinase
  • ICP6 also does not have a functional TM domain and it does not localize to the cell surface (Conner, J. Murray, J.,
  • PK activity of pp29 lal has some properties different from the authentic ICP10 PK, presumably because it lacks pan of PK catalytic domain VI (Luo '91 ).
  • the TM domain is also required (but insufficient) for PK activity (Luo, J. H. and Aurelian. L.
  • the transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of Herpes simplex virus type 2 ribonucleolide reductase. Journal of Biological Chemistry, Vol.
  • the unique Hpal site within the ICP10 coding region represents the 3' end of the transforming region (Jariwalla '80) and Hpal cuts the gene after the codon for amino acid residue 417. It is not known whether pp29 lal has transforming activity. However, PK activity is required for neoplastic potential. PK negative mutants do not transform cells. This includes a mutant deleted in the TM domain and site directed mutants in the ATP binding sites ( Lys 1 6 and/or Lys" 59 ) or the ion-binding site (Glu 209 ) (Smith C. C, Luo, J. H., Hunter, J. C. R.. Ordonez, J. V., and Aurelian, L.
  • the transmembrane domain of the large subunit of HSV-2 ribonucleolide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that results in ras activation.
  • a PK ' mutant deleted only in the TM domain does not have transforming activity (Smith '94)
  • DNA sequences that code for ICP10 amino acids 106-41 1 but lack PK activity are not intrinsically neoplastic. This demonstrates that: (i) the HSV-2 oncoprotein is located within ICP10 amino acids 1 -41 1 , and (ii) neoplastic potential requires a functional PK activity.
  • ICP10 PK in virus growth/pathogenesis The function of ICP10 PK in virus growth/pathogenesis is unknown.
  • the HSV-2 ICP10 protein has int ⁇ nsic PK activity. This was shown by demonstrating that ICP10 PK activity is lost through site-directed mutagenesis.
  • the oncoprotein also has SH3-binding motifs at positions 140, 149 and 396, which are required for interaction with signaling proteins. This interaction is required for transforming activity. Site directed mutagenesis was used to identify amino acids required for kinase activity and interaction with signaling proteins.
  • ICP10PK functions as a growth factor receptor involved in signaling and it binds the adaptor protein Grb, in vitro It has also been shown that there are SH3-bind ⁇ ng sites within the ICP10 PK domain (at positions 140. 149 and 396) and they are required for interaction with signaling proteins and, thereby transformation (Nelson , J W., Zhu, J., Smith, C. C, Kulka. M. and Aure an, L ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus tvpe 2 of ribonucleolide reductase (ICP10). Journal of Biological Chemistn 271, pp 17021-17027, 1996) [Nelson '96]. Mutation of the ICP10 pro ne-nch motifs at position 396 and 149 reduced Grb : binding 20- and 2-fold respectively.
  • the ICP 10 PK catalytic domain also contains amino acids that are responsible for binding a down-regulator of PK activity (ras-GAP) They are located at position 106-178.
  • ICP10 ⁇ PK The construction of a virus deleted in ICP10 amino acids 106-446 (ICP10 ⁇ PK) is described by Peng '96 Briefly, the wild type sequences in a plasmid (TP101 ) that contains the HSV-2 BamHI E and T fragments were replaced w ith the 1 8kb Sall/Bglll fragment from pJHL9 pJHL9 is a plasmid containing an ICP10 mutant deleted in the PK catalytic domain '92). The resulting plasmid, TP9, contains sequences w hich code for ICP10 deleted in the PK catalytic domain flanked by 4 and 2.8 kb of HSV-2 DNA sequences at the 5' and 3' ends, respectively.
  • the lOkb Hindlll/EcoRI fragment from TP9 was introduced by marker transfer into a virus (ICP 10 ⁇ RR) in which the RR domain of ICP 10 had been replaced with the LacZ gene
  • ICP10 ⁇ PK The resulting recombinant virus, designated ICP10 ⁇ PK. w as obtained by selecting white plaques on a background of blue plaques after staining ith X-gal. A few white plaques w ere picked, purified and grown in Vero cells w ith 10% serum.
  • the ICP10 ⁇ PK v irus is deleted in ICP 10 amino acids 106-446 It lacks ICP 10 PK activity and retains RR activitv (Peng '96) and is attenuated for growth in culture and in infected animals
  • the v irus induces HSV -specific T cell immunitv and protects mice from challenge w ⁇ h w I Id type HSV-2 99/36087
  • a cross recombinant vaccine such as disclosed in US 4,554,159 (' 159), does not suffer from the problems of the subunit vaccines, but contains the oncogene present in HSV- 2. Unless care is taken to define and delete the oncogene. the cross recombinant vaccine could induce cancer in the vaccinee.
  • the cross recombinant of '159 is temperature sensitive. Avirulence may be obtained by selecting temperature resistance, but the temperature of the mouse is 39°C while that of humans is 37°C. This temperature sensitivity could well render such a cross problematic in a vaccine.
  • a superior method of selection of avirulence is by the removal of genes coding for virulence without respect to the temperature at which the virus replicates. Also, the use of prototypical crosses would preclude the use of gene deleted or inserted mutants. Due to the many type-common epitopes on HSV- 1 and HSV-2, cell-mediated immunity cross-reacts (Jacobs, R. P., Aurelian. L.. and Cole, G. A.
  • a live vaccine is supe ⁇ or to a dead vaccine because the liv e vaccine induces herd immunity; it induces different types of immunity, such as mucosal. cell mediated and humoral immunity.
  • a higher le el of immunity is normally obtained because the virus titers are increased through replication vv ithin the vaccinee.
  • a live vaccine is of longer duration, thus obviating boosters and lowering initial dosage.
  • the ICP I O ⁇ PK virus is deleted in ICP 10 ammo acids 106-446 It lacks ICP 10 PK activity and retains RR activity (Peng '96) and is attenuated for grow th in culture and in infected animals.
  • the virus induces HSV- specific T cell immunity and protects mice from challenge w ith ild type HSV-2
  • a patent 99/36087
  • HSV-1 Most developed vaccines (viz. those in neurovirulence genes) are in HSV-1.
  • Known vaccines are not virus type-specific. All known vaccines for HSV-1 or HSV-2 are cross- reactive and provide immunity to the other virus type.
  • HSV-1 is not as desirable a vaccine candidate against he ⁇ es, because the major clinical problem is the sexually transmitted HSV-2, which is also associated with cancer induction.
  • Recent studies indicate that the age-adjusted prevalence of HSV-2 in the US is now 20.8%, an increase of approximately 30% over the past 13 years (Fleming, D.T.. McQuillan. G. M.. Johnsons, R. E., Nahmias. A. J., Aral. S. 0. Lee, F. K..
  • HSV-2 infection A new concern about HSV-2 infection is that it may facilitate the spread of HIV and increase the severity of the disease.
  • HSV-1 has only a 50%) homology to HSV-2, this may lower the response rate against the heterologous strain in the vaccinated population.
  • Another absolute requirement for a live vaccine is the absence of lesions upon immunization.
  • An important trait in the live vaccine is its ability to induce high levels of HSV-specific T cell immunity and prevent lesions due to infection with wild type HSV-2 and
  • a desirable trait in the live vaccine would also be its ability to cause a reduction in the frequency of recurrent lesions in a person already infected. There is a substantial population already infected with HSV who may have intercourse with uninlected individuals who would benefit from such a vaccine.
  • the present invention solves all the problems recited above providing a w hole live attenuated HSV-2 in which the HSV-2 has a deletion of the oncot-ene. has strong 99/36087
  • the present invention provides a method of immunizing a subject against HSV-1 or HSV-2 with said vaccine composition, providing a supenor method of conferring immunity upon the subject.
  • the present invention is a vaccine composition comp ⁇ sing He ⁇ es Simplex V ⁇ rus-2 recombinant selected from the group of recombinants which have deletions in the gene for ICP 10 to remove the fragments encoding for amino acids 107-351 (AuV 351) , the fragments encoding for amino acids 107-375 (AuV375) and the fragments encoding for amino acids 107- 417 (AuV417), and a pharmaceutically acceptable earner or diluent.
  • Fig. 1 Schematic representation of the construction of AuV351 DNA
  • Fig 2 Schematic representation of the construction of AuV375 DNA
  • Fig 3 Schematic representation of the construction of AuV417 DNA
  • v e w hole HS V-2 has been mutated and attenuated to prevent neoplastic transformation
  • the mutated HSV-2 can be formulated w ith immune 99/36087
  • the protein kinase (PK) domain of the large subunit of ⁇ bonucleotide reductase (ICP 10) has previously been shown to have oncogenic properties Deletion of the PK domain was shown to have delete ⁇ ous effects on the abi tv of HSV-2 to infect cells
  • the present invention consists of the construction of three viruses that have various deletions in the ICP10 PK domain These deletions encompass the minimal kinase catalytic region but do not include antigenic sites downstream thereof The mutants are, therefore, PK negative, growth attenuated, and do not have oncogenic potential Unlike the recombinant virus (ICPIO ⁇ PK) previously constructed (Peng 96), they have supenor immunogenicity Computer assisted analysis of the ICP 10 PK antigenicity profile indicates that many antigenic sites are clustered within amino acids 350-450 Because these amino acids are not required for PK activity (Luo
  • HSV-2 RR activity depends on the binding of the two RR subunits (RR1 and RR2) at RR1 sites located within amino acids 419-432 and the extreme C-terminal 145 codons (Chung, T D , Luo, J H , Wymer, J P., Smith, C C and urehan, L .
  • recombinant viruses that retain these amino acids are likely to have a higher RR activity.
  • the increased RR activity may provide an advantage in that the recombinant viruses do not have defects other than the PK which is required for the expression of the regulatory IE genes. As such they will retain attenuated growth mediated by the absence of ICP 10 PK while evidencing improved in vivo expression required for increased immunogenicity (also favored by the retention of amino acids within positions 350-450).
  • RR activity was assayed as described (Averett, D. R.. Lubbers. C, Ehon. G. B., and Spector, T Ribonucleolide reductase induced by herpes simplex virus type 1. Characterization of a distinct enzyme Journal of Biological Chemisti ⁇ 258, pp.9631-9638, 1983) in the absence or presence of 0.5 mM ohgopeptides located at various ICP 10 amino acids (aa).
  • HSV-1 and HSV-2 v iruses are very similar.
  • the DNA is 50% 0 homologous.
  • Virtually all viral proteins have both t pe-specific and type common epitopes. For all but 2 proteins (i.e.. for 82 proteins), the type-common epitopes are predominant. The exception is the HSV-
  • HSV-2 oncoprotein ICP10PK both of which elicit predominantly type-specific antibodies.
  • HSV-2 oncogene was deleted from ICPIO ⁇ PK Therefore we only have one protein that can induce tvpe specific immunity The remaining 83 proteins will induce type common immunity This incudes both antibody and cell mediated immunity.
  • v e whole HSV-2 could not be explored as a vaccine option for HSV since the oncogene had potential neoplastic implications for the patient.
  • the present invention demonstrates that by removing the oncogene, a protein kinase, from the HSV-2 genome, not only are the neoplastic properties removed, but the virus is attenuated and provides full protection against challenge for an extended pe ⁇ od of time
  • HSV-2 strain which contains the deleted oncogene is not c ⁇ tical to the present inv ention
  • examples of such strains include HSV-2(G), HSV-2(333), HSV-2(186), HSV-2(S-1), although anv strain is acceptable
  • PK oncogene
  • the construction of the mutant virus is accomplished by well known techniques.
  • the location of the oncogene (PK) is well-known (DNA Tumor Viruses Oncogenic Mechanisms, Ed C Barbanti-Brodano. et al , Plenum Press, NY, 1995, chapter 14 by L Aurelian, Transformation and Mutagenic Effects Induced by He ⁇ es Simplex Virus Types 1 and 2, pp.
  • the oncogene is located in the ICP 10 section of the HSV-2 genome It has previously been shown that the PK activity and oncogenic activity are located within the gene sequence encoding amino acids 88-41 1 Bneflv, the wild type sequences in a plasmid (TP101) that contains the HSV-2 BamHI E and T fragments are replaced with vanous fragments from pJHL2 [ICP10 mutant deleted in the PK domain (Luo '92)] The resulting plasmids contain sequences which code for ICP 10 deleted in the PK catalytic domain flanked by 4 and 2.8 kb of HSV-2 DNA sequences at the 5' and 3' ends, respectively The lOkb
  • Hindlll'EcoRI fragment from these plasmids are introduced by marker transfer into a virus (ICP10 ⁇ RR) in which the RR domain of ICP 10 had been replaced with the LacZ gene.
  • the resulting recombinant v iruses designated AuV351.
  • AuV375 and AuV 417 are obtained by selecting w hue plaques on a background of blue plaques after staining w ith X-gal A few white plaques are picked and purified
  • the hyb ⁇ dizing bands, seen in the recombinant viruses are smaller than the 7.6kb for wild type HSV-2.
  • the band seen for AuV351 DNA is 6.9kb.
  • that seen for AuV375 DNA is 2.2 kb and that seen for AuV417 DNA is 6.6 kb as compared to 7 6kb for HSV-2 or the restored viruses AuV351(R), AuV375(R) ⁇ nd AuV417(R) DNA.
  • the recombinant viruses can be differentiated from wild type HSV-2 by DNA analysis and by lmmunoprecipitation/immunoblotting w ith antibody to epitopes located at ICP 10 amino acids retained by the deleted protein, such as the ant ⁇ -LA-1 antibody (recognizes ICP10 amino acids 13-26) (Aure an, et al.. Cancer Cells 7, pp.187-191, 1989).
  • the proteins recognized by the antibody are significantly smaller than the 140kDa ICP10 protein.
  • AuV41 7 is 99 kDa
  • AuV375 is 104 kDa
  • AuV351 is 107 kDa.
  • the oncogene or any portion thereof may be deleted.
  • e mean any portion of the oncogene w hich once deleted results in attenuation of the virus and prevents neoplastic transformation of the cells. Determining if PK activitv is absent requires expression of the viral gene and subjecting the result to standard
  • PK assays (Chung '89) There is abundant guidance in the p ⁇ or art as to the sections of the ICP 10 gene hich is required for PK activity. Determining viral attenuation requires testing in animals to determine absence of lesion formation. The techniques for accomplishing this are standard and well-known in the art. The resultant mutant viruses are used in infection experiments and compared to infections ith wild-type HSV-2 and the restored viruses. The cells used in infection are not critical to the present invention. Any human or animal cell line which can be infected with ild type HSV-2 may be used in the present invention Examples of such cell lines include Vero cells, HeLa cells, 293 cells, or MRC5 cells (all av ailable from American Type Culture Collection, Rockville. Maryland). ICPIO ⁇ PK can also be grown in cells that constitutively express ICP10. for example JHLal . It is titrated by plaque assay on Vero cells with MEM- 10% FCS and 0.3% human IgG
  • Immunizing a subject indicates the standard inte ⁇ retation w ell known in the art. Upon administration w ith the v accine composition, neutralizing antibodies and cell-mediated immunity are raised in the subject and said antibodies and cell-mediated immunity confer immunity to the subject 99/36087
  • the present invention teaches immunization of a subject against HSV-2.
  • a "pfu” is a plaque forming unit and represents the quantity of virus required to form a single plaque when a cell culture is infected with the virus. It is a quantitative measure of viral infectivity used by those skilled in the art. Due to the 50% homology of HSV-1 and HSV-2 there will be a high degree of protection against HSY- 1 infection.
  • viruses AuV351 , AuV375 and AuV417 for human use is accomplished by suspension in a solution with or without stabilizing ingredients, and with or without immune stimulants and adjuvants.
  • stabilizing agents, immune stimulants, and adjuvants include alum, incomplete Freud's adjuvant, MR-59 (Chiron, Emeryville. CA), MPL (mono-phosphoryl Lipid A).
  • Such stabilizing agents, adjuvants and immune stimulants are well known in the art and can be used singly or in combination.
  • the vaccine composition of the present invention can be administered to any animal, including humans.
  • the vaccine composition may be administered via any suitable mode of administration, such as intramuscular, oral, subcutaneous, intradermal, intravaginal. rectal, or intranasal administration.
  • a prefened mode of administration is subcutaneous or intradermal administration.
  • the AuV351 , AuV375 and AuV417 viruses which provide protection against HSV-2 infection, can be administered along with a pharmaceutically acceptable earner or diluent.
  • pharmaceutically acceptable earner or diluents include water, phosphate buffered saline or sodium bicarbonate buffer.
  • a number of other acceptable carriers or diluents are known
  • the strategy for construction of AuV351 is to create a recombinant plasmid, pAu ⁇ 351 that contains a gene cassette deleted in ICP 10 amino acids 107-351 (Fig. 1 )
  • This plasmid is used for the generation of a recombinant HSV-2 v irus deleted in ICP 10 amino acids 10"-351 through recombination w ith the appropriate v iral DNA All details of cloning methodology are based on standard procedures
  • Plasmid pJL2 (Luo '92) is digested w ith BamHI (made blunt ended) and StuI to remov e the 732bp fragment that encodes amino acids 107-351 The resulting construct is 99/36087
  • plasmid pAu ⁇ 351 contains sequences which code for ICP 10 deleted in amino acids 107-351 flanked by 4 and 2.8kb of HSV-2 DNA sequences at the 5' and 3' ends, respectively.
  • Hindlll/EcoRI fragment from pAu ⁇ 351 is introduced by marker transfer into a virus (ICP10 ⁇ RR) in which the RR domain of ICP 10 has been replaced with the LacZ gene.
  • the resulting recombinant designated AuV351 is obtained by selecting white plaques on a background of blue plaques after staining with X-gal. A few white plaques are picked, punfied. and grown in Vero cells in MEM with 10%> FCS.
  • Vero cells are co-transfected with l ⁇ g of infectious viral DNA from AuV351 and a 10-fold molar excess of the wild type BamHI E, T fragment.
  • Southern blot hyb ⁇ dization is used to confirm that the AuV351 DNA is deleted in nucleotides encoding ICP 10 amino acids 107-351
  • Viral DNA is isolated from cytoplasmic vinons as descnbed (Pignatti et al.. Virology, Vol 93, pp 260-264, 1979; Smith et al., Journal of General Virology, Vol 73. pp.1417-1428. 1992). Briefly, Vero cells are infected at a multiplicity of infection (moi ) of 5. At 48 hrs.
  • post infection (p.i.) cells are resuspended (2 x 10 7 cell/ml) in a buffer consisting of 10 mM T ⁇ s-HCl (pH 7.9), 10 mM EDTA and 0.25% Triton. Following incubation on ice ( 15 mm.), NaCl is added at a final concentration of 0.2 M and the nuclei are precipitated by centnfugation at 1 ,000 x g ( 10 min. 4°C). The supernatant, containing cytoplasmic vinons.
  • Viral DNA 15 ⁇ g is digested w ith BamH I and the fragments are separated by 1% agarose gel electrophoresis in a T ⁇ s-Acetate EDTA (TAE) buffer (40 mM T ⁇ s-acetate and 1 mM EDTA) It is transferred to Gene screen membranes ( New England Nuclear Co ⁇ ., Beverly. MA) and the membranes are incubated in a preh b ⁇ dization solution containing 5 x 99/36087
  • the hyb ⁇ dization probe is o gonucleotide AU26 (CCCCTTCATCATGTTT.AAGGA) hich represents a sequence m the ICP 10 RR coding region It is 3' tailed w ith digoxigenin-dUTP (DIG-dUTP ) by terminal transferase ( Boeh ⁇ nger Mannheim, Indianapolis, IN) in 20 ⁇ l volume with lx reaction buffer
  • the membranes are nnsed in Buffer 1(100 m.M T ⁇ s-HCl. pH 7 5.150 mM NaCl), incubated in Buffer 2 [2% (w ) casein in Buffer 1 ] for 40m ⁇ n and in Buffer 2 containing 3xl 0 U/ml of alkaline phosphatase-conjugatcd anti-digoxigenin antibody (Boeh ⁇ nger Mannheim, Indianapolis, IN) for 30 min After washing w ith Buffer 1 (twice) and soaking in Buffer 3 ( 100 mM T ⁇ s-HCl, pH 9 5, 100 mM NaCl. 50 mM MgCl, for 2 mm. the membranes are exposed to the chemiluminescent substrate Lumi-PhosTM 530 (Boeh ⁇ nger Mannheim, Indianapolis. IN) and the reaction is developed on X-ray film
  • DNA ( 15 ⁇ g) from HSV-2, AuV351 or AuV351 (R) is digested with BamHI. separated on 1 % agarose gels and transfened to nylon membranes. It is hybndized with the AU26 probe which recognizes a sequence within the ICP 10 RR coding region A hybridizing 7 6kb band which represents the BamHI E fragment is observed for HSV-2. and AuV351(R) DNA The hyb ⁇ dizing band seen for AuV351 DNA is 6.9kb.
  • Example 2 Constniction and Characterization of the AuV375 virus and AnV ⁇ 7 (R)
  • the strategy for construction of AuV375 is to create a recombinant plasmid, pAu ⁇ 375 that contains a gene cassette deleted in ICP 10 amino acids 107-375 (Fig. 1 )
  • This plasmid is used for the generation of a recombinant HSV-2 irus deleted in ICP 10 amino acids 107-375 through recombination w ith the approp ⁇ ate iral DN ⁇
  • All details of cloning methodology are based on standard procedures Plasmid pJL2 (Luo '92) is digested w ith EcoNI (partial) and BamHI to remove the
  • plasmid p ⁇ 375 The wild type sequences in a plasmid (TP 101 ) that contains the HSV-2 BamHI E and T fragments (Peng 96) are replaced with the 2 3kb Sall/Bglll fragment from p ⁇ 375
  • the resulting plasmid, pAu ⁇ 375 contains sequences which code for ICP10 deleted in amino acids 107-375 flanked by 4 and 2 8kb of HSV-2 DNA sequences at the 5' and 3' ends, respectively
  • the 10 3kb Hindlll EcoRI fragment from pAu ⁇ 375 is introduced by marker transfer into a virus (ICPIO ⁇ RR) in which the RR domain of ICP 10 has been replaced with the LacZ gene The resulting recombinant.
  • AuV375 is obtained by selecting white plaques on a background of blue plaques after staining with X-gal. A few white plaques are picked, pu ⁇ fied, and grown in Vero cells in MEM with 10% FCS
  • Vero cells are co-transfected with l ⁇ g of infectious viral DNA from AuV375 and a 10-fold molar excess of the wild type BamHI E/T fragment
  • a strategy similar to that reported for ICP6 ⁇ Goldstein and Weller, Virology, Vol 166, pp 41-51 , 1988) is used to select restored virus under growth rest ⁇ cted conditions (1 % FCS) Southern blot hybridization is used to confirm that the AuV375 DNA is deleted in nucleotides encoding ICP 10 amino acids 107-375 as descnbed in Example 1
  • DNA 15 ⁇ g from HSV-2, AuV375 or AuV375(R) is digested with BamHI, separated on 1%, agarose gels and transferred to nylon membranes It is hybndized with the AU26 probe which recognizes a sequence within the ICP 10 RR coding region A hybndizing 7 6kb band which represents the BamHI E fragment is observed for
  • Example 3 Construction and Characte ⁇ zation of the AuV417 virus and A ⁇ V417(R ⁇ ).
  • the strategy for construction of AuV417 is to create a recombinant plasmid, pAu ⁇ 417 that contains a gene casette deleted in ICP 10 amino acids 107-417 (Fig 3)
  • This plasmid is used for the generation of a recombinant HSV-2 virus deleted in ICP 10 amino acids 107-417 through recombination w ith the approp ⁇ ate v iral DNA
  • All details of cloning methodology are based on standard procedures
  • Plasmid pJL2 (Luo '92) is digested w ith BamHI (made blunt-ended) and Hpal to remov e the 936bp fragment that encodes amino acids 107-417 The resulting construct is collapsed through ligation at the BamHI EcoM sites to generate plasmid p ⁇ 41 7
  • the wild type sequences in a plasmid (TP101 ) that contains the HSV-2 BamHI E and T fragments 99/36087
  • pAu ⁇ 417 contains sequences which code for ICP 10 deleted in amino acids 107-417 flanked by 4 and 2.8kb of HSV-2 DNA sequences at the 5' and 3' ends, respectively.
  • the 10. lkb Hindlll/EcoRI fragment from pAu ⁇ 417 is introduced by marker transfer into a virus (ICPIO ⁇ RR) in which the RR domain of ICP 10 has been replaced with the LacZ gene.
  • the resulting recombinant designated AuV417 is obtained by selecting white plaques on a background of blue plaques after staining with X-gal A few white plaques are picked, pu ⁇ fied, and grown in Vero cells in MEM with 10% FCS
  • Vero cells are co-transfected with l ⁇ g of infectious viral DNA from AuV417 and a 10-fold molar excess of the wild type BamHI E/T fragment.
  • a strategy similar to that reported for ICP6 ⁇ Goldstein and Weller, Virology, Vol. 166, pp 41-51, 1988) is used to select restored virus under growth restncted conditions ( 1% FCS).
  • AuV375 and uV417 have hiaher RR activity than ICPI O ⁇ PK ICPIO ⁇ PK virus has RR activity, but it is lower than that of HSV-2 Inasmuch as amino acids 413-438 may be involved in the complexation of the two RR subunits (Table 1), viruses that retain these amino acids have an RR activity similar to that of HSV-2 (Table 2).
  • Example 5 AuV351 .
  • AuV.75 and AuV417 are attenuated for growth in infected nmmals
  • the mouse footpad model of HSV-2 infection is used to examine the growth of
  • Example 6 AnVlSI .
  • AuV375 and AuV417 protect from HSV-2 challenge
  • the footpad model described in example 5 is used to examine protection by AuV351, AuV375 and AuV417
  • the expe ⁇ ment is done as previously descnbed (Wachsman '89; Wachsman '92) with mice given one or multiple immunizations with IxlO 7 pfu of virus (at 14-16 days intervals) before challenge with wild type HSV-2 Challenge is with IxlO 7 to IxlO 8 pfu of HSV-2 and it is done at 3-6 weeks after the last immunization All mice in the
  • PBS group develop skin lesions from which virus is isolated, and 50-80% die on days 8-13 after challenge Bv contrast lesions are not seen and virus is not isolated from the immunized mice
  • the AuV351 , AuV375 and AuV417 v noises have vaccine potential.
  • Example 7 AuV351 , AuV375 and AuV417 viruses induce HSV-specific immunity.
  • mice are immunized with AuV351, AuV375 and AuV417 as descnbed in example 6 Two-four weeks after the last injection spleens are removed and T cells are used in lymphocyte proliferation assays as descnbed (Wachsman et al Journal of General Virology, Vol 70, pp 2513-2520, 1989, Vaccine, Vol 10, pp 447-454, 1992) HSV-specific lymphoproliferation is seen in all animals Prohferative levels are similar to those seen for
  • AuV375 and AuV417 induce good levels of virus-specific T cell responses They also induce antibody responses as determined by neutralization assays
  • All references cited herein are inco ⁇ orated by reference in their entirety It will be apparent to those skilled in the art that the examples and embodiments descnbed herein are bv wav of illustration and not of limitation, and that other examples may be utilized w ithout departing from the spi ⁇ t and scope of the present invention, as set forth in the appended claims

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne de nouvelles compositions de vaccin contre le virus de l'herpès simplex qui contiennent un virus HSV-2 actif entier dans lequel plusieurs acides aminés ont été supprimés; ainsi que des procédés d'utilisation de ces compositions de vaccin.
PCT/US1999/000922 1998-01-20 1999-01-15 Nouvelles compositions de vaccin contre le virus de l'herpes simplex Ceased WO1999036087A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22314/99A AU2231499A (en) 1998-01-20 1999-01-15 Novel vaccine compositions for herpes simplex virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US922598A 1998-01-20 1998-01-20
US09/009,225 1998-01-20

Publications (1)

Publication Number Publication Date
WO1999036087A1 true WO1999036087A1 (fr) 1999-07-22

Family

ID=21736353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000922 Ceased WO1999036087A1 (fr) 1998-01-20 1999-01-15 Nouvelles compositions de vaccin contre le virus de l'herpes simplex

Country Status (2)

Country Link
AU (1) AU2231499A (fr)
WO (1) WO1999036087A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370283A4 (fr) * 2000-11-16 2004-12-15 Univ Maryland Prevention des maladies virales recurrentes
EP3139745A4 (fr) * 2014-05-09 2017-11-08 Board of Supervisors of Louisiana State University And Agricultural and Mechanical College Vaccins contre les infections de l'herpès simplex génital

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AURELIAN L, ET AL.: "AMINO-TERMINAL EPITOPE OF HERPES SIMPLEX VIRUS TYPE 2 ICP10 PROTEINAS A MOLECULAR DIAGNOSTIC MARKER FOR CERVICAL INTRAEPITHELIAL NEOPLASIA", CANCER CELLS, COLD SPRING HARBOR, NY, US, 1 January 1989 (1989-01-01), US, pages 187 - 191, XP002917747, ISSN: 1042-2196 *
MILLIGAN G N, BERNSTEIN D I: "GENERATION OF HUMORAL IMMUNE RESPONSES AGAINST HERPES SIMPLEX VIRUSTYPE 2 IN THE MURINE FEMALE GENITAL TRACT", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 206, 1 January 1995 (1995-01-01), AMSTERDAM, NL, pages 234 - 241, XP002917744, ISSN: 0042-6822, DOI: 10.1016/S0042-6822(95)80038-7 *
MURTHY S C S, TRIMBLE J J, DESROSIERS R C: "DELETION MUTANTS OF HERPESVIRUS SAIMIRI DEFINE AN OPEN READING FRAME NECESSARY FOR TRANSFORMATION", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 63, no. 08, 1 August 1989 (1989-08-01), US, pages 3307 - 3314, XP002917746, ISSN: 0022-538X *
NELSON J W, ET AL.: "ATP AND SH3 BINDING SITES IN THE PROTEIN KINASE OF THE LARGE SUBUNIT OF HERPES SIMPLEX VIRUS TYPE 2 OF RIBONUCLEOTIDE REDUCTASE (ICP10)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 29, 1 July 1996 (1996-07-01), US, pages 17021 - 17027, XP002917748, ISSN: 0021-9258, DOI: 10.1074/jbc.271.7.3417 *
PARR M B, ET AL.: "A MOUSE MODEL FOR STUDIES OF MUCOSAL IMMUNITY TO VAGINAL INFECTION BY HERPES SIMPLEX VIRUS TYPE 2", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC., vol. 70, no. 03, 1 January 1994 (1994-01-01), The United States and Canadian Academy of Pathology, Inc., pages 369 - 380, XP002917745, ISSN: 0023-6837 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370283A4 (fr) * 2000-11-16 2004-12-15 Univ Maryland Prevention des maladies virales recurrentes
EP3139745A4 (fr) * 2014-05-09 2017-11-08 Board of Supervisors of Louisiana State University And Agricultural and Mechanical College Vaccins contre les infections de l'herpès simplex génital
US10130703B2 (en) 2014-05-09 2018-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccines against genital herpes simplex infections
US10596253B2 (en) 2014-05-09 2020-03-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccines against genital herpes simplex infections
EP3753573A1 (fr) * 2014-05-09 2020-12-23 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Vaccins contre les infections de l'herpès simplex génital
US11229697B2 (en) 2014-05-09 2022-01-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccines against genital herpes simplex infections

Also Published As

Publication number Publication date
AU2231499A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
US6541459B1 (en) Soluble herpesvirus glycoprotein complex vaccine
Marchioli et al. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells
US5171568A (en) Recombinant herpes simplex gb-gd vaccine
EP1047446B1 (fr) Composition de vaccin contre le virus de l'herpes simplex et son procede d'utilisation
JP2599350B2 (ja) 膜結合性タンパク質を含有するワクチン類
RU2158308C2 (ru) Мутант gp 50 для приготовления векторной вакцины, векторная вакцина и способ ее получения
US5648079A (en) Herpes simplex virus glycoprotein B vaccine
Meignier et al. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus
JP4486055B2 (ja) １型ウシヘルペスウイルスの欠失突然変異体、それに基づくワクチンおよび１型ウシヘルペスウイルスを検出するためのキット
Heineman et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs
US6013265A (en) Vaccine composition for herpes simplex virus and methods of using
Kweon et al. Bovine herpes virus expressing envelope protein (E2) of bovine viral diarrhea virus as a vaccine candidate
AU707837B2 (en) Non-splicing variants of gp350/220
EP0605680B1 (fr) Mutants du virus de la rhinotracheite infectieuse bovine et vaccins
US5807557A (en) Soluble herpesvirus glycoprotein complex
US7592169B2 (en) Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US20130064844A1 (en) Non-splicing variants of gp350/220
CA2195099A1 (fr) Vaccin polynucleotidique contre le virus de l'herpes
WO1999036087A1 (fr) Nouvelles compositions de vaccin contre le virus de l'herpes simplex
JP2003235588A (ja) Ｈｓｖの治療的処置に用いるワクチン
Epstein Recent progress with vaccines against Epstein-Barr virus infection
DK173597B1 (da) Fremgangsmåde til fremstilling af et membranfrit trunkat af et membranbundet polypeptid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/008099

Country of ref document: MX

122 Ep: pct application non-entry in european phase